On October 25, 2022 Hangzhou Celgenyx reported that it completed a $14 million Series A Round to support development of its off-the-shelf cell therapies, either through partnerships or its own R&D (Press release, Hangzhou Celgenyx, OCT 25, 2022, View Source [SID1234622467]). All of the capital was contributed by Vivo Partners from an RMB fund. Hangzhou Celgenyx is a development-stage biotech, dedicated to the acquisition and development of next-gen cell immunotherapies for malignant cancers. Celgenyx expects to complete construction of a 3000 square meter R&D center and GMP pilot production base in Hangzhou before the end of 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!